Insilico Medicine publishes CDK8/19 novel inhibitor powered by generative chemistry platform to treat multiple cancers
Among the cyclin-dependent kinases (CDKs), CDK8 and CDK19 regulate signal-induced, context-specific transcription reprogramming and play key roles in cell proliferation and differentiation. As previous studies have noted, the inhibition of CDK8/19 could suppress cancer cell proliferation and metastasis, thus posing a potential therapy for hematological